Cidara Therapeutics Announces Sale of Rezafungin Acetate Assets to NAPP

Details

entered into an Asset Purchase Agreement with NAPP Pharmaceutical Group Limited, a subsidiary of Mundipharma Medical Company, to sell all of its rezafungin acetate assets. This transaction includes the sale of intellectual property rights, product data, regulatory approvals, inventory, and specified contracts. In connection with the sale, Cidara also amended its Melinta License Agreement to modify regulatory milestones. The sale is expected to provide Cidara with financial and strategic benefits while allowing NAPP to advance the development and commercialization of rezafungin acetate.

Items reported

About Cidara Therapeutics Inc.

Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.